OPEN ACCESS Freely available online

ISSN: 2684-1622
Journal of Eye Diseases and Disorders

Perspective

Role of Diabetic Nephropathy as a Risk Factor for Age-related Macular Degeneration

Cring Roy*

Department of Optometry, Aston University, Birmingham, United Kingdom

DESCRIPTION

Diabetic nephropathy and age-related macular degeneration (AMD) are two debilitating diseases that affect millions of people worldwide. While these conditions may seem unrelated on the surface, emerging research suggests a potential causal relationship between diabetic nephropathy and the development of AMD. To explore this intriguing connection, scientists have turned to Mendelian randomization studies, a powerful tool in epidemiology that can help establish causal relationships between risk factors and diseases. Diabetic nephropathy is a common complication of diabetes mellitus and is a leading cause of kidney disease and renal failure. It occurs when the high levels of glucose in the blood damage the small blood vessels in the kidneys, ultimately leading to impaired kidney function. Age-related macular degeneration, on the other hand, is a progressive eye condition that primarily affects the central part of the retina, known as the macula. As the macula deteriorates over time, central vision becomes blurry or distorted, making it difficult to read, drive, or recognize faces. Recent epidemiological studies have shown an increased risk of AMD in individuals with diabetic nephropathy. While these observational studies suggest a correlation, they cannot prove causality. This is where Mendelian randomization studies come into play. Mendelian randomization (MR) is an innovative approach that leverages genetic variants as instrumental variables to assess causality between a risk factor (in this case, diabetic nephropathy) and an outcome (AMD). The rationale behind MR is that genetic variants are randomly allocated during conception and are not influenced by environmental factors. Therefore, they can be used as proxies to estimate the long-term effects of a particular risk factor. To investigate the potential causal relationship between diabetic nephropathy and AMD, researchers conducted a Mendelian randomization study. They identified genetic variants associated with diabetic nephropathy and used them as instrumental variables. By analyzing a large dataset of individuals with and without these genetic variants, they could infer whether diabetic nephropathy had a causal effect on AMD development. The Mendelian randomization study provided compelling evidence suggesting that diabetic nephropathy may indeed causally contribute to the development of AMD. This finding has important implications for public health and clinical practice. Identifying individuals with diabetic nephropathy at risk for AMD could lead to earlier detection and intervention. Ophthalmologists and nephrologists may collaborate to monitor these patients closely and implement preventive measures to protect their vision. Understanding the causal link between these conditions may shed light on shared risk factors or biological pathways. This knowledge could grow for the development of targeted therapies that address the common underlying mechanisms. Patients with diabetic nephropathy should be educated about the potential risk of AMD, emphasizing the importance of regular eye exams and lifestyle modifications to mitigate these risks. While this Mendelian randomization study provides valuable insights, more research is needed to delve deeper into the complex relationship between diabetic nephropathy and AMD. Longitudinal studies and clinical trials can help validate these findings and explore potential interventions. The Mendelian randomization study on the causality of diabetic nephropathy and age-related macular degeneration is a significant step forward in our understanding of these two prevalent conditions. It suggests that diabetic nephropathy may play a causal role in the development of AMD, highlighting the importance of early detection and intervention. As we continue to project the intricacies of these diseases, we move closer to more effective prevention and treatment strategies that can improve the lives of millions affected by diabetic nephropathy and AMD.

Correspondence to: Cring Roy, Department of Optometry, Aston University, Birmingham, United Kingdom, E-mail: cringroy@gmail.com

Received: 18-Aug-2023, Manuscript No. JEDD-23-23249; **Editor assigned:** 21-Aug-2023, Pre QC No. JEDD-23-23249 (PQ); **Reviewed:** 06-Sep-2023, QC No JEDD-23-23249; **Revised:** 13-Sep-2023, Manuscript No. JEDD-23-23249 (R); **Published:** 21-Sep-2023, DOI: 10.35248/2684-1622.23.8.213

Citation: Roy C (2023) Role of Diabetic Nephropathy as a Risk Factor for Age-related Macular Degeneration. J Eye Dis Disord. 8:213.